tiprankstipranks
Horizon Therapeutics (HZNP)
NASDAQ:HZNP

Horizon Therapeutics Stock Price & Analysis

1,266 Followers

HZNP Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$57.84 - $120.54
Previous Close$62.97
Volume3.69M
Average Volume (3M)2.73M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$833.32M
Total Debt (Recent Filing)$1.02B
P/E Ratio19.4
Beta1.04
Next EarningsNov 07, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)3.24
Shares Outstanding230,384,373
R-Squared0.26
Standard Deviation0.12
10 Day Avg. Volume2,921,089
30 Day Avg. Volume2,727,500
P/B Ratio52.88
P/S Ratio3.81
P/CF Ratio10.50
P/FCF Ratio12.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside77.86% Upside
Rating ConsensusStrong Buy
Alpha0.02
Number of Analyst Covering11


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

HZNP FAQ

What was Horizon Therapeutics’s price range in the past 12 months?
Horizon Therapeutics lowest stock price was $57.84 and its highest was $120.53 in the past 12 months.
    What is Horizon Therapeutics’s market cap?
    Currently, no data Available
    When is Horizon Therapeutics’s upcoming earnings report date?
    Horizon Therapeutics’s upcoming earnings report date is Nov 07, 2022 which is in 43 days.
      How were Horizon Therapeutics’s earnings last quarter?
      Horizon Therapeutics released its earnings results on Aug 03, 2022. The company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.327 by -$0.257.
        Is Horizon Therapeutics overvalued?
        According to Wall Street analysts Horizon Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Horizon Therapeutics pay dividends?
          Horizon Therapeutics does not currently pay dividends.
          What is Horizon Therapeutics’s EPS estimate?
          Horizon Therapeutics’s EPS estimate is $1.07.
            How many shares outstanding does Horizon Therapeutics have?
            Horizon Therapeutics has 230,384,370 shares outstanding.
              What happened to Horizon Therapeutics’s price movement after its last earnings report?
              Horizon Therapeutics reported an EPS of $1.07 in its last earnings report, missing expectations of $1.327. Following the earnings report the stock price went down -18.471%.
                Which hedge fund is a major shareholder of Horizon Therapeutics?
                Among the largest hedge funds holding Horizon Therapeutics’s share is Paulson & Co Inc. It holds Horizon Therapeutics’s shares valued at 494M.

                  ---

                  Horizon Therapeutics Stock Analysis

                  Smart ScoreOutperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  8
                  The Horizon Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Horizon Therapeutics

                  Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Alkermes
                  Prothena
                  Amarin
                  Novartis
                  Roche Holding

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis